Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?

J Clin Transl Hepatol. 2020 Jun 28;8(2):222-229. doi: 10.14218/JCTH.2020.00026. Epub 2020 Jun 18.

Abstract

The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden; yet, there is still a lack of approved methods to prevent or reverse liver fibrosis. Therefore, effective hepatic antifibrotic drugs are urgently needed. The activation and proliferation of hepatic stellate cells are still the mechanisms of fibrosis that remain the focus of therapeutic research. In recent years, significant progress has been made in the development and applicability of antifibrosis drugs. In this review, we summarize the effectiveness and safety of available antifibrosis drugs utilizing different targets. In addition, some characteristics of antifibrosis drugs in phase II and III trials are introduced in detail.

Keywords: Antifibrotic agents; Fibrosis; Liver; Pharmacotherapy; Reversal.

Publication types

  • Review